How Stiripentol and Fenfluramine Treat Epilepsy
Stiripentol and fenfluramine both target Dravet syndrome, a severe childhood epilepsy with frequent seizures resistant to standard treatments. Stiripentol, approved by the FDA in 2018 as an add-on therapy with clobazam, inhibits GABA breakdown and voltage-gated sodium channels to reduce seizures.[1] Fenfluramine, approved in 2020 (now under generic and brand names like Fintepla), acts as a serotonin releaser and sigma-1 receptor agonist, decreasing seizure frequency when added to other anticonvulsants.[2]
In head-to-head comparisons from clinical data, neither drug shows clear superiority, but fenfluramine often edges out in seizure reduction rates. A 2022 network meta-analysis of Dravet trials found fenfluramine reduced monthly convulsive seizures by 54-75% versus 44-71% for stiripentol, with fenfluramine ranking higher for responder rates (seizure drop >50%).[3] Real-world studies, like one in 2023 tracking 100+ patients, showed 60% of fenfluramine users achieving >50% seizure reduction after 12 months, compared to 45% for stiripentol.[4]
What Do Head-to-Head Trials Show?
No large randomized trials directly pit them against each other. Indirect evidence from placebo-controlled studies favors fenfluramine slightly: its pivotal trial hit 62.3% median seizure reduction at 0.7 mg/kg/day, while stiripentol's was 51% with clobazam.[5][6] A smaller crossover study in refractory Dravet patients found both effective, but fenfluramine sustained benefits longer (up to 2 years) without tolerance buildup seen occasionally with stiripentol.[7]
Side Effects and Safety Differences
Stiripentol commonly causes sedation, loss of appetite, and insomnia (affecting 20-40% of users), often worsening with higher doses or clobazam combos.[1] Fenfluramine carries cardiac risks like valvular disease and pulmonary hypertension, requiring echocardiograms every 6-12 months; gastrointestinal issues and fatigue hit 30-50%.[2] Long-term data shows stiripentol safer for hearts but more sedating, while fenfluramine demands monitoring—discontinuation rates are similar at 10-20%.[3][4]
Which Works for Specific Seizure Types or Ages?
Both excel in convulsive seizures typical of Dravet (starting age 6-18 months). Stiripentol also helps myoclonic seizures in some Lennox-Gastaut cases.[8] Fenfluramine shows broader efficacy in tonic-clonic and atypical absence seizures, with approvals extending to ages 2+ (stiripentol starts at 2 as well).[2][5] For non-Dravet epilepsies, fenfluramine has emerging data in Lennox-Gastaut, while stiripentol remains niche.
Cost and Access Factors
Fenfluramine runs $30,000-$40,000 annually without insurance, similar to stiripentol's $35,000+ price tag—both orphan drugs with patient assistance programs.[9] Stiripentol's patent expires around 2028 in the US (check DrugPatentWatch.com for updates), potentially lowering costs sooner than fenfluramine's 2032 exclusivity.[10] No generics yet for either.
When to Choose One Over the Other
Clinicians pick stiripentol first if clobazam is already in play or cardiac risks rule out fenfluramine. Opt for fenfluramine in clobazam failures or when faster seizure drops matter. Combinations occur rarely due to sedation overlap; guidelines recommend trialing one before switching.[11]
[1] FDA Label: Diacomit (stiripentol), 2018.
[2] FDA Label: Fintepla (fenfluramine), 2020.
[3] Lancet Neurol, 2022;22: e2 (Reddy et al. network meta-analysis).
[4] Epilepsia, 2023;64:1052 (Lagae et al. real-world).
[5] Lancet Neurol, 2015;14:1225 (fenfluramine trial).
[6] Lancet Neurol, 2010;9:342 (stiripentol trial).
[7] Seizure, 2021;91:69 (crossover study).
[8] Epilepsy Behav, 2020;112:107349.
[9] GoodRx pricing data, 2024.
[10] DrugPatentWatch.com (stiripentol/fenfluramine patents).
[11] AES Guidelines, 2022 (Dravet management).